Drug Profile
Research programme: eye disorders therapy - Curia/Alcon
Latest Information Update: 13 Oct 2021
Price :
$50
*
At a glance
- Originator Albany Molecular Research Inc; Alcon
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Eye disorders
Most Recent Events
- 09 Apr 2019 Novartis completed the spin-off of Alcon
- 02 May 2007 Albany Molecular Research is now called AMRI
- 07 Jan 2007 Discontinued - Preclinical for Eye disorders in USA (unspecified route)